Former Rubius CEO jumps to another Flagship spinout

Published on 17 Nov 2022 on American City Business Journals

Pablo Cagnoni, who was CEO of the soon-to-shutter Rubius Therapeutics Inc. until earlier this year, has joined another Flagship Pioneering-backed...

Read the rest of the article

Start tracking your investments with Statfolio

Innovators across Massachusetts' life sciences industry are busy developing drugs and devices to...

American City Business Journals 21 Sep 2023

Meanwhile, Insulet promoted two other executives. Mark Field, a former Thermo Fisher Scientific I...

American City Business Journals 11 May 2023

Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Investing.com 6 Mar 2023

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%

Investing.com 6 Mar 2023

Investing.com 6 Mar 2023

In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range o...

Benzinga via Yahoo Finance 22 Feb 2023

A Cambridge biotech is set to become at least the 10th Massachusetts biotech company to shut down...

American City Business Journals 18 Jan 2023

Pablo Cagnoni, who was CEO of the soon-to-shutter Rubius Therapeutics Inc. until earlier this yea...

American City Business Journals 17 Nov 2022

Rubius Therapeutics Inc. is in the final days of its existence. The Flagship Pioneering spinout...

American City Business Journals 3 Nov 2022

Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic altern...

Benzinga via Yahoo Finance 3 Nov 2022